Servicio de Oncología Médica del Hospital General Universitario de Elche, Carrer Almazara, 11, 03203, Elche, Alicante, Spain.
Servicio de Oncología Médica del Hospital Universitario de Fuenlabrada, Madrid, Spain.
Clin Transl Oncol. 2024 Sep;26(9):2109-2115. doi: 10.1007/s12094-024-03433-4. Epub 2024 Mar 21.
Tuberculosis is one of the infectious diseases with greater morbidity and mortality worldwide. Cancer causes an important immunosuppression with increased risk of infections. There is an enlarged bidirectional incidence between tuberculosis and cancer, mainly due to latent tuberculosis.
There is great discrepancy between recommendations for screening and prophylaxis of latent tuberculosis in patients with solid tumors and systemic cancer therapy among different medical societies and guidelines. Most infectious diseases guidelines recommend it, while most oncology guidelines do not.
Patients with solid tumours generally have a limited life expectancy and a state of intermittent immunosuppression, resulting in a lower risk of tuberculosis reactivation than other risky populations. There is a lack of prospective and retrospective studies analysing the benefit of screening and prophylaxis in this population. The first step is to study the incidence of active tuberculosis in this population to estimate the real magnitude of the problem.
结核病是全球发病率和死亡率较高的传染病之一。癌症会导致严重的免疫抑制，增加感染的风险。结核病和癌症之间存在双向发病率增加，主要是由于潜伏性结核病。
不同医学协会和指南中，实体瘤和全身癌症治疗患者的潜伏性结核病筛查和预防建议存在很大差异。大多数传染病指南推荐进行筛查和预防，而大多数肿瘤学指南则不推荐。
实体瘤患者的预期寿命有限，且处于间歇性免疫抑制状态，因此与其他高危人群相比，结核病复发的风险较低。目前缺乏前瞻性和回顾性研究来分析该人群筛查和预防的获益。第一步是研究该人群中活动性结核病的发病率，以评估实际问题的严重程度。
